Latest Property Portfolio News

Charter Hall (ASX: CHC) has won a $1.2 billion diversified direct property mandate from an existing institutional client, reinforcing its growth trajectory in funds under management and showcasing its sector expertise across Australia.

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) has received FDA Investigational New Drug clearance to initiate a pivotal clinical trial of its cell therapy Ryoncil in children with Duchenne Muscular Dystrophy, aiming to address inflammation-driven disease progression.

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) reported net sales of US$30.3 million for its FDA-approved cellular therapy Ryoncil in the March quarter, bringing total revenue since launch close to US$100 million. Strong sales in February and March offset January’s seasonal dip.

US Masters Residential Property Fund (ASX:URF) has announced an on-market buy-back program for up to 68.8 million fully paid stapled securities, representing approximately 10% of its units on issue. The buy-back will run from April 7, 2026, to April 6, 2027, and will be conducted through Taylor Collison Limited.

Energy Technologies Limited, via its subsidiary Cogenic, has acquired Maradin Ltd’s laser optical engineering IP portfolio, positioning itself at the forefront of laser projection technology for AR, VR, and defence applications.

AdAlta Limited has been granted a key Canadian patent for its anti-fibrotic drug AD-214, completing its composition of matter protection across all major commercial markets. This milestone strengthens the company’s intellectual property portfolio and underpins its commercial strategy for AD-214.

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.

Endeavour Group reported a solid first half for fiscal 2026 with underlying EBIT of $563 million, supported by retail price leadership and strong hotel sales growth. The group raised capital expenditure guidance, reflecting accelerated hotel renewals and strategic investments.

Opthea Limited reports a striking turnaround with a $339.9 million profit for H1 2026, driven by a strategic refocus on developing OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The company plans a rebrand and ASX reinstatement as it charts a new course in rare respiratory health.

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

Weebit Nano Limited has reported a remarkable 8-fold increase in revenue, driven by a landmark licensing agreement with Texas Instruments and significant progress in its ReRAM technology commercialisation.